Pancreatic

Pancreatic
2025-09-05T00:00:00.000+10:00
Ongoing

AMP945-PC-202

AMP945-PC-202
Pancreatic

A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of narmafotinib in Combination with modified FOLFIRINOX in Pancreatic Cancer Patients.

AMP945-PC-202 is a Phase 1b/2a clinical trial testing AMP945 (narmafotinib), a focal adhesion kinase inhibitor, in patients with metastatic pancreatic cancer.

Trial overview

Clinical Area

Medical Oncology

Disease

Pancreatic

Disease site

Gastrointestinal

Study Phase

I

Trial Identifiers

Registration number: NCT07026279

https://clinicaltrials.gov/study/NCT07026279

GenesisCare Location(s)
Principal Investigator(s)
Medical Oncologist

Prof. Nick Pavlakis

BSc MBBS MMed PhD FRACP

Prof. Nick Pavlakis
location pin icon

Frenchs Forest (Oncology) +1

View Profile
Profile Image - Prof. Nick Pavlakis

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.